Trevena (TRVN) Trading 5.2% Higher

Trevena Inc (NASDAQ:TRVN)’s share price traded up 5.2% during trading on Monday . The stock traded as high as $2.03 and last traded at $2.02. 945,802 shares were traded during mid-day trading, an increase of 9% from the average session volume of 867,671 shares. The stock had previously closed at $1.92.

Several equities analysts have commented on the stock. Oppenheimer set a $5.00 price objective on shares of Trevena and gave the company a “buy” rating in a report on Monday, March 12th. HC Wainwright upped their price objective on shares of Trevena to $7.00 and gave the company a “buy” rating in a report on Thursday, March 8th. Cowen reiterated a “buy” rating and issued a $10.00 price objective on shares of Trevena in a report on Monday, May 7th. ValuEngine upgraded shares of Trevena from a “strong sell” rating to a “sell” rating in a report on Wednesday, May 2nd. Finally, Zacks Investment Research downgraded shares of Trevena from a “buy” rating to a “hold” rating and set a $2.00 price objective on the stock. in a report on Saturday, January 20th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $5.63.

The firm has a market cap of $137.30 million, a P/E ratio of -1.55 and a beta of -0.54. The company has a debt-to-equity ratio of 0.35, a quick ratio of 4.11 and a current ratio of 4.11.

Trevena (NASDAQ:TRVN) last released its quarterly earnings data on Thursday, May 3rd. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.05. equities research analysts expect that Trevena Inc will post -0.8 EPS for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the stock. Millennium Management LLC acquired a new position in shares of Trevena in the fourth quarter valued at about $130,000. American Century Companies Inc. acquired a new position in shares of Trevena in the fourth quarter valued at about $135,000. JPMorgan Chase & Co. grew its stake in shares of Trevena by 635.7% in the first quarter. JPMorgan Chase & Co. now owns 89,228 shares of the biopharmaceutical company’s stock valued at $146,000 after acquiring an additional 77,100 shares in the last quarter. Bourgeon Capital Management LLC grew its stake in shares of Trevena by 59.3% in the fourth quarter. Bourgeon Capital Management LLC now owns 137,800 shares of the biopharmaceutical company’s stock valued at $220,000 after acquiring an additional 51,300 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. grew its stake in shares of Trevena by 55.0% in the first quarter. Schwab Charles Investment Management Inc. now owns 144,362 shares of the biopharmaceutical company’s stock valued at $237,000 after acquiring an additional 51,200 shares in the last quarter. Institutional investors and hedge funds own 48.11% of the company’s stock.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, develops therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. Its product candidates include OLINVO injection, a G protein biased ligand of the µ opioid receptor that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in Phase I clinical study for the treatment of migraine; and TRV734, a small molecule G protein biased ligand of the µ opioid receptor that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure.

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply